Growth Metrics

Eli Lilly (LLY) Long-Term Deferred Tax (2017 - 2025)

Historic Long-Term Deferred Tax for Eli Lilly (LLY) over the last 9 years, with Q3 2025 value amounting to $9.0 billion.

  • Eli Lilly's Long-Term Deferred Tax rose 2124.37% to $9.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 billion, marking a year-over-year increase of 2124.37%. This contributed to the annual value of $8.0 billion for FY2024, which is 4606.83% up from last year.
  • Latest data reveals that Eli Lilly reported Long-Term Deferred Tax of $9.0 billion as of Q3 2025, which was up 2124.37% from $9.4 billion recorded in Q2 2025.
  • Eli Lilly's 5-year Long-Term Deferred Tax high stood at $9.4 billion for Q2 2025, and its period low was $2.4 billion during Q2 2022.
  • Over the past 5 years, Eli Lilly's median Long-Term Deferred Tax value was $3.8 billion (recorded in 2023), while the average stood at $4.9 billion.
  • Per our database at Business Quant, Eli Lilly's Long-Term Deferred Tax tumbled by 1205.13% in 2021 and then soared by 9611.51% in 2023.
  • Over the past 5 years, Eli Lilly's Long-Term Deferred Tax (Quarter) stood at $2.5 billion in 2021, then rose by 12.2% to $2.8 billion in 2022, then surged by 96.12% to $5.5 billion in 2023, then skyrocketed by 46.07% to $8.0 billion in 2024, then rose by 12.03% to $9.0 billion in 2025.
  • Its Long-Term Deferred Tax was $9.0 billion in Q3 2025, compared to $9.4 billion in Q2 2025 and $8.6 billion in Q1 2025.